3 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
Follow Stalevo: new trials by email Literature Review of Stalevo trials Research Report on Stalevo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 IPX066, CLE - Parkinson's Disease | Phase 3 | Completed | Impax Laboratories, LLC | 110 | 2010-05-01 | 2019-10-29 |
| A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg) - Parkinson's Disease | Phase 3 | Completed | Novartis | 493 | 2005-08-01 | 2017-05-17 |
| Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa - Parkinson's Disease | Phase 3 | Completed | Novartis Pharmaceuticals | 747 | 2004-09-01 | 2012-04-23 |
Parkinson Disease (3) · Dyskinesias (2)
Impax Laboratories, LLC (1) · Novartis (1) · Novartis Pharmaceuticals (1)
Italy (3) · United States (3) · Canada (2) · France (2) · Germany (2) · Turkey (Türkiye) (2) · Austria (1) · Belgium (1) · Czechia (1) · Finland (1) · Greece (1) · Israel (1) · Poland (1) · Portugal (1) · Spain (1)